Cybin Company Presentation

Natwaine Gardner, M.D. — Director of Product Development o Worked as a publishing research analyst for more than 10 years, most recently at Sprott Capital Partners. o Prior to joining Sprott Capital Partners, he was a top ranked analyst at Scotiabank covering the healthcare sector. o Before working in the capital markets, Mr. Ridgeway held a postdoctoral fellowship at Harvard Medical School where he performed cancer research. o Mr. Ridgeway holds a Ph.D. in Biochemistry from Western University, an MBA from Queen’s University and is a CFA® Charterholder. o Vast experience in mushroom cultivation in Europe since 2006 with further knowledge in sclerotia production for the Dutch markets and mycelium sub- strain isolation and cultivation preparation. o Experience in product formulation, infusion and delivery mechanisms. o Transitioned genetics, cultivation and extraction expertise into the cannabis industry and consulted with multiple companies on output efficiency both in the USA and Canada. o Current Vice Dean and Medical Director of the Caribbean School of Medical Sciences , Jamaica (CSMSJ) and is a graduate of the University of the West Indies, Mona. o Holds a Doctor of Philosophy in Biochemistry as well as a medical degree from the Higher Institute of Medical Sciences of Havana, Cuba. o Over 50 peer-reviewed publications. o Currently serves as a member of the Medicinal Cannabis Unit (MCU) Advisory Board Committee, Ministry of Health; and as a consultant to the Economic Growth Council on Cannabis-related matters; the Cannabis Licensing Authority (CLA), The Bureau of Standards; for Protocol Development and Research for cannabis. o Biochemist by profession, Dr. Gardner holds a wealth of knowledge in applied organic chemistry and in research and product development. Dr. Gardner has obtained a BSc Biotechnology (hons) and PhD Biotechnology (high 7 commendation) from the University of the West Indies, Mona in the areas of substance abuse and addiction treatment. o Numerous peer reviewed articles in the field of treating substance use disorders and has most recently served as a consultant to implementing the Medicinal Cannabis Unit, Ministry of Health; as well as in research and product development focusing on cannabis-related products. o Over 50 peer-reviewed publications. o Former Lead Compliance Program Designer of the non-medical cannabis compliance program at a major Canadian retailer. o ISO 19600 Certified Senior Lead Compliance Manager and PROSCI Certified Change Management Practitioner. o Vast knowledge in design and operation of "audit ready" compliance programs, regulatory and operations risk identification, mitigation, corrective action and management. Executive Research, Clinical and Regulatory Team 26 P r i v a t e & C o n f i d e n t i a l Lorenzo Gordon, M.D. — Director of Research James Andrews — Chief Cultivation & Extraction Officer Lori Challenger — Director of Operations & Compliance Alan Ridgeway Ph.D. — Healthcare Research Advisor Sherri M. Altshuler — Regulatory Advisor o Partner and Co-Chair of Capital Markets Group at Aird & Berlis LLP. o Recognized in 2017 as one of Lexpert magazine's Rising Stars: Canada's Leading Lawyers Under 40 and, in 2018, as a leading lawyer to watch in the area of Corporate Finance & Securities. Also recognized as a leading lawyer in Cannabis Law by Chambers Canada and The Best Lawyers in Canada. o Member of the TSX Venture Exchange Ontario Advisory Committee and a former member of the Ontario Securities Commission Small and Medium Enterprises Committee. o Instructor of Corporate Finance course at Windsor Law School.